Ionis Pharmaceuticals CEO Brett Monia (L) and Kardigan CEO Tassos Gianakakos
At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis
When some former MyoKardia execs reunited with $300 million for a new “heart health” biotech earlier this year, they were
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
